Jamie E. Chaft
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- CAR-T cell therapy research
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 88
- Lung Cancer Diagnosis and Treatment 55
- Gastric Cancer Management and Outcomes 7
- Oncology 87
- Cancer Immunotherapy and Biomarkers 55
- Lung Cancer Research Studies 26
- Colorectal Cancer Treatments and Studies 11
- HER2/EGFR in Cancer Research 7
- Co-authors
- Mark G. Kris (66 shared papers)Matthew D. Hellmann (34 shared papers)Gregory J. Riely (22 shared papers)Marc Ladanyi (17 shared papers)Maria E. Arcila (18 shared papers)Camelia S. Sima (15 shared papers)Valerie W. Rusch (24 shared papers)Andrew J. Plodkowski (10 shared papers)
- Journals
- Journal of Clinical Oncology (50 papers)Journal of Thoracic Oncology (23 papers)Annals of Oncology (11 papers)Journal of Thoracic and Cardiovascular Surgery (7 papers)Clinical Cancer Research (6 papers)
- Partner nations
- United StatesJapanSpain
In The Last Decade
Jamie E. Chaft
169 papers receiving 10.4k citations
Jamie E. Chaft's Hit Papers
Peers
Comparison fields: 5 of 119
- Oncology 5.4k
- Pulmonary and Respiratory Medicine 5.1k
- Cancer Research 1.2k
- Immunology 855
- Genetics 370
Countries citing papers authored by Jamie E. Chaft
This map shows the geographic impact of Jamie E. Chaft's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jamie E. Chaft with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jamie E. Chaft more than expected).
Fields of papers citing papers by Jamie E. Chaft
This network shows the impact of papers produced by Jamie E. Chaft. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jamie E. Chaft. The network helps show where Jamie E. Chaft may publish in the future.
Co-authors
The 25 scholars most cited alongside Jamie E. Chaft, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 178 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 729 |
| 2 | Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer Hit paper breakdown → | 2018 | 653 |
| 3 | Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis Hit paper breakdown → | 2014 | 605 |
| 4 | Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer Hit paper breakdown → | 2023 | 510 |
| 5 | Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer Hit paper breakdown → | 2016 | 495 |
| 6 | Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study Hit paper breakdown → | 2016 | 485 |
| 7 | Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint Hit paper breakdown → | 2014 | 427 |
| 8 | Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 ( HER2 ) Tyrosine Kinase Mutations in Lung Adenocarcinomas Hit paper breakdown → | 2012 | 371 |
| 9 | EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics Hit paper breakdown → | 2013 | 352 |
| 10 | Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design Hit paper breakdown → | 2011 | 335 |
| 11 | 2018 | 268 | |
| 12 | Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update Hit paper breakdown → | 2017 | 245 |
| 13 | Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer Hit paper breakdown → | 2021 | 242 |
| 14 | 2020 | 233 | |
| 15 | 2015 | 219 | |
| 16 | 2016 | 216 | |
| 17 | 2018 | 198 | |
| 18 | 2015 | 174 | |
| 19 | 2011 | 164 | |
| 20 | 2018 | 146 |
About Jamie E. Chaft
Jamie E. Chaft is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Surgery and Radiology, Nuclear Medicine and Imaging, having authored 178 papers that have together received 10.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (88 papers), Cancer Immunotherapy and Biomarkers (55 papers), Lung Cancer Diagnosis and Treatment (55 papers), Lung Cancer Research Studies (26 papers), Cancer Genomics and Diagnostics (24 papers), Colorectal Cancer Treatments and Studies (11 papers), HER2/EGFR in Cancer Research (7 papers) and Gastric Cancer Management and Outcomes (7 papers). The work is most often cited by research in Oncology (5.4k citations), Pulmonary and Respiratory Medicine (5.1k citations), Cancer Research (1.2k citations), Immunology (855 citations) and Genetics (370 citations). Jamie E. Chaft has collaborated with scholars based in United States, Japan and Spain. Frequent co-authors include Mark G. Kris, Matthew D. Hellmann, Gregory J. Riely, Marc Ladanyi, Maria E. Arcila, Camelia S. Sima, Valerie W. Rusch, Andrew J. Plodkowski, Maureen F. Zakowski and William D. Travis. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Oncology, Journal of Thoracic and Cardiovascular Surgery and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.